INTERLEUKIN-2 (IL-2) is a T-cell derived molecule implicated in the clonal expansion of antigen-activated T cells¹ and in T-cell development². IL-2 is also implicated in autoimmune disease³, although its role is still controversial^4,5. Murine systemic lupus erythematosus (SLE) is a good model for human SLE as most of the immunological abnormalities in the human disease also seem to be operative in the mouse⁶. Among SLE mice, the MRL/lpr strain develops early in life autoimmune diseases such as immune complex-mediated glomerulonephritis, arthritis and arteritis^7,8. Lymphoid abnormalities associated with those diseases in this strain are thymic atrophy and abnormal proliferation of CD3⁺ CD4⁻ CD8⁻ 'double-negative' T cells, resulting in massive generalized lymph node enlargement. We have therefore now examined the effects of IL-2 on the disease progression in MRL/lpr mice⁹ using live vaccinia recombinant viruses expressing the human IL-2 gene¹⁰. Vaccinated mice showed prolonged survival, decreased autoantibody and rheumatoid factor titres, marked attenuation of kidney interstitial infiltration and intraglomerular proliferation, as well as clearance of synovial mononuclear infiltrates. Inoculation with the IL-2/vaccinia recombinant virus led, in addition, to drastic reduction of the double-negative T-cell population, improved thymic differentiation and restoration of normal values of mature cells in peripheral lymphoid organs.